Ultragenyx Pharmaceutical Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(446,444) | $(435,798) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 115,711 | 117,866 |
| Amortization of discount on marketable debt securities, net | (3,484) | (9,818) |
| Depreciation and amortization | 26,215 | 26,464 |
| Non-cash royalty revenue | (74,419) | (67,406) |
| Non-cash interest expense on liabilities for sales of future royalties | 42,531 | 47,519 |
| Other | (2,693) | (4,679) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 2,834 | (12,958) |
| Inventory | (6,150) | (8,751) |
| Prepaid expenses and other assets | (7,260) | 12,269 |
| Accounts payable, accrued, and other liabilities | (13,012) | 607 |
| Net cash used in operating activities | (366,171) | (334,685) |
| Investing activities: | ||
| Purchase of property, plant, and equipment | (5,062) | (6,837) |
| Purchase of marketable debt securities | (32,445) | (392,680) |
| Proceeds from sale of marketable debt securities | 143 | 3,148 |
| Proceeds from maturities of marketable debt securities | 361,884 | 290,675 |
| Payments for intangible asset | (15,000) | (12,500) |
| Other | (1,273) | (2,309) |
| Net cash provided by (used in) investing activities | 308,247 | (120,503) |
| Financing activities: | ||
| Proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net | — | 380,983 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | 79,728 | — |
| Proceeds from the issuance of common stock under equity plan awards, net of tax | 4,080 | 8,072 |
| Proceeds from issuance of equity from noncontrolling interest | — | 7,000 |
| Net cash provided by financing activities | 83,808 | 396,055 |
| Effect of exchange rate changes on cash | 4,656 | (52) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,540 | (59,185) |
| Cash, cash equivalents and restricted cash at beginning of period | 184,159 | 219,399 |
| Cash, cash equivalents and restricted cash at end of period | $214,699 | $160,214 |
| Supplemental disclosures of non-cash information: | ||
| Stock-based compensation capitalized into ending inventory | $2,780 | $3,202 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.